Skip to content

Nuvectis Pharma, Inc. NVCT Total Current Liabilities

Total Current Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$19.16B-20.4%
Pfizer logo
PfizerPFE
$34.35B-5.8%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$10.54M+13.2%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$12.89M+146%
Nuvation Bio logo
Nuvation BioNUVB
$79.52M+50.7%
Immunome logo
ImmunomeIMNM
$27.41M-11.0%

Other financials

Income statement

See full
Operating income-$6.3M-12.4%
Net income-$6.1M-13.5%
EPS (diluted)-$0.26+3.7%

Balance sheet

See full
Cash & equivalents$25.1M-15.9%
Total equity$14.2M-32.1%
Total assets$25.4M-15.8%

Cash flow

See full
Operating cash flow-$6.5M-56.0%

Valuation

See full
Market cap$739.27M+335%

Returns & leverage

See full
Return on equity-154.4%+79.4pp
Current ratio2.3×-1.0×

Where this comes from

Reported directly by Nuvectis Pharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvectis Pharma, Inc.'s total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvectis Pharma, Inc.'s total current liabilities?
Nuvectis Pharma, Inc. (NVCT) reported total current liabilities of $11.18M in Q1 2026.
How has Nuvectis Pharma, Inc.'s total current liabilities changed year-over-year?
Nuvectis Pharma, Inc.'s total current liabilities increased by 21.6% year-over-year, from $9.19M to $11.18M.
What is the long-term trend for Nuvectis Pharma, Inc.'s total current liabilities?
Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s total current liabilities has grown at a 53.1% compound annual growth rate (CAGR), from $2.42M to $13.3M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.